Cardiff Oncology, Inc. (CRDF) appointed Mani Mohindru, PhD, as President and Chief Executive Officer, effective April 9 2026, following her interim tenure. The company also named Josh Muntner as Chief Financial Officer, effective April 6 2026, and Ajay Aggarwal, MD, MBA, as Chief Operating Officer, effective April 27 2026.
Mohindru brings a decade of oncology research experience and has led clinical programs at multiple biotechnology firms. Muntner is a seasoned capital‑market professional who has raised more than $300 million for life‑science companies. Aggarwal has over 15 years of clinical operations and program execution expertise in the pharmaceutical industry.
The new leadership team is expected to accelerate the development of onvansertib, Cardiff’s lead candidate, and to guide the company through upcoming regulatory milestones. Onvansertib, a PLK1 inhibitor, achieved a 72.2 % objective response rate in the 30 mg arm of its Phase 2 trial for RAS‑mutated metastatic colorectal cancer, compared with 43.2 % for standard of care.
Cardiff’s management emphasized that the appointments strengthen the organization’s strategic execution and financial stewardship as the company prepares for critical Phase 2 data readouts and seeks additional financing to support its projected annual burn of approximately $45.9 million. The company’s cash reserves were $60.6 million as of September 30 2025 and $58.3 million as of December 31 2025, providing a runway into the first quarter of 2027.
The appointments also position Cardiff to pursue a potential Phase 3 program and partnership opportunities. The company has a $15 million investment from Pfizer and a collaboration that grants Pfizer rights to onvansertib data, underscoring the strategic importance of the drug and the need for robust leadership to navigate the competitive metastatic colorectal cancer market.
Mohindru said the new team will help advance onvansertib and secure the financing needed to reach the next milestones, and that building the right team is central to the company’s strategy and to ultimately delivering a new therapy to patients in need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.